# Comparing Injection Frequency Between Aflibercept and Ranibizumab in Patients With CRVO With a Treat& Extend Regimen

> **NCT02274259** · PHASE4 · COMPLETED · sponsor: **Anders Kvanta** · enrollment: 40 (actual)

## Conditions studied

- Central Retinal Vein Occlusion

## Interventions

- **DRUG:** Aflibercept
- **DRUG:** Ranibizumab

## Key facts

- **NCT ID:** NCT02274259
- **Lead sponsor:** Anders Kvanta
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-10
- **Primary completion:** 2015-06
- **Final completion:** 2016-12
- **Target enrollment:** 40 (ACTUAL)
- **Last updated:** 2020-12-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02274259

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02274259, "Comparing Injection Frequency Between Aflibercept and Ranibizumab in Patients With CRVO With a Treat& Extend Regimen". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02274259. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*